Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder
- PMID: 10591284
- DOI: 10.1001/archpsyc.56.12.1088
Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder
Abstract
Background: Intent-to-treat analyses of the study revealed that medication management, alone or combined with intensive behavioral treatment, was superior to behavioral treatment and community care in reducing attention-deficit/hyperactivity disorder (ADHD) symptoms; but only combined treatment showed consistently greater benefit than community care across other outcome domains (disruptive and internalizing symptoms, achievement, parent-child relations, and social skills). We examine response patterns in subgroups defined by baseline variables (moderators) or variables related to treatment implementation (mediators).
Methods: We reconducted random-effects regression (RR) analyses, adding factors defined by moderators (sex, prior medication use, comorbid disruptive or anxiety disorder, and public assistance) and a mediator (treatment acceptance/attendance).
Results: Study outcomes (N = 579) were upheld in most moderator subgroups (boys and girls, children with and without prior medication, children with and without comorbid disruptive disorders). Comorbid anxiety disorder did moderate outcome; in participants without anxiety, results paralleled intent-to-treat findings. For those with anxiety disorders, however, behavioral treatment yielded significantly better outcomes than community care (and was no longer statistically different from medication management and combined treatment) regarding ADHD-related and internalizing symptoms. In families receiving public assistance, medication management yielded decreased closeness in parent-child interactions, and combined treatment yielded relatively greater benefits for teacher-reported social skills. In families with high treatment acceptance/attendance, intent-to-treat results were upheld. Acceptance/attendance was particularly important for medication treatments. Finally, two thirds of children given community care received stimulants. Behavioral treatment did not significantly differ from, but medication management was superior to, this subgroup.
Conclusions: Exploratory analyses revealed that our study (the Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder [MTA]) results were confirmed across most baseline variables and treatment acceptance/attendance. In children with ADHD plus anxiety, behavioral treatment surpassed community care and approached medication-based treatments regarding parent-reported ADHD symptoms.
Comment in
-
Development of clinical services for attention-deficit/hyperactivity disorder.Arch Gen Psychiatry. 1999 Dec;56(12):1097-9. doi: 10.1001/archpsyc.56.12.1097. Arch Gen Psychiatry. 1999. PMID: 10591285 No abstract available.
-
MTA findings fail to consider methodological issues.Arch Gen Psychiatry. 2001 Dec;58(12):1184-7. doi: 10.1001/archpsyc.58.12.1184-a. Arch Gen Psychiatry. 2001. PMID: 11735850 No abstract available.
Similar articles
-
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.Arch Gen Psychiatry. 1999 Dec;56(12):1073-86. doi: 10.1001/archpsyc.56.12.1073. Arch Gen Psychiatry. 1999. PMID: 10591283 Clinical Trial.
-
Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers.J Dev Behav Pediatr. 2001 Feb;22(1):60-73. doi: 10.1097/00004703-200102000-00008. J Dev Behav Pediatr. 2001. PMID: 11265923 Clinical Trial.
-
Attention-deficit hyperactivity disorder, multimodal treatment, and longitudinal outcome: evidence, paradox, and challenge.Wiley Interdiscip Rev Cogn Sci. 2015 Jan-Feb;6(1):39-52. doi: 10.1002/wcs.1324. Epub 2014 Nov 3. Wiley Interdiscip Rev Cogn Sci. 2015. PMID: 26262927
-
In the wake of the MTA: charting a new course for the study and treatment of children with attention-deficit hyperactivity disorder.Can J Psychiatry. 1999 Dec;44(10):999-1006. doi: 10.1177/070674379904401006. Can J Psychiatry. 1999. PMID: 10637679 Review.
-
Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.Pediatrics. 2005 Jun;115(6):e749-57. doi: 10.1542/peds.2004-2560. Pediatrics. 2005. PMID: 15930203 Review.
Cited by
-
European clinical guidelines for hyperkinetic disorder -- first upgrade.Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I7-30. doi: 10.1007/s00787-004-1002-x. Eur Child Adolesc Psychiatry. 2004. PMID: 15322953
-
The role of primary care physicians in attention-deficit/hyperactivity disorder.Pediatr Ann. 2002 Aug;31(8):475-84. doi: 10.3928/0090-4481-20020801-07. Pediatr Ann. 2002. PMID: 12174762 Free PMC article. No abstract available.
-
Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA).J Abnorm Child Psychol. 2000 Dec;28(6):527-41. doi: 10.1023/a:1005179014321. J Abnorm Child Psychol. 2000. PMID: 11104315 Clinical Trial.
-
Psychiatric comorbidities in children with attention deficit hyperactivity disorder: implications for management.Paediatr Drugs. 2003;5(11):741-50. doi: 10.2165/00148581-200305110-00003. Paediatr Drugs. 2003. PMID: 14580223 Review.
-
Evidence-based treatment for mental disorders in children and adolescents.Curr Psychiatry Rep. 2002 Apr;4(2):93-100. doi: 10.1007/s11920-002-0041-6. Curr Psychiatry Rep. 2002. PMID: 11914169 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical